Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.

Oefelein M

The Journal of urology1 Jan 2003Cited by 22 (Europe PMC)

PMID12478147DOI10.1016/s0022-5347(05)64079-7PepBankPUB-12478147

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, short-term overall health-related quality of life improved significantly from baseline with testosterone-guided goserelin re-dosing.
In plain wordsIn men with prostate cancer, short-term quality of life improved from baseline with testosterone-guided goserelin re-dosing.
Peptide
Goserelin
Outcome
IncreaseShort-term overall health-related quality of life
Study
n = 22
Comparator
Baseline
Analysis
Primary
Outcome group
Quality of life · Cancer
Studied dose
10.8 mgAs given in this study (human).
Source sentences
Summary
Short-term overall health related quality of life and patient satisfaction were significantly improved over baseline measurements.
3 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Summary · context
Health related quality of life using the Expanded Prostate Index Composite and SF-36 instruments was the primary outcome assessed.
Report a problemFND-1247814706
02HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, overall health-related quality of life at study completion was equivalent regardless of goserelin dosing method.
In plain wordsIn men with prostate cancer, quality of life at study completion was equivalent between goserelin dosing methods.
Peptide
Goserelin
Outcome
No significant changeOverall health-related quality of life at completion
Study
n = 22
Comparator
Alternative dosing method
Analysis
Primary
Outcome group
Quality of life · Cancer
Studied dose
10.8 mgAs given in this study (human).
Source sentences
Summary
However, by study completion overall health related quality of life was equivalent regardless of the dosing method.
3 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Summary · context
Health related quality of life using the Expanded Prostate Index Composite and SF-36 instruments was the primary outcome assessed.
Report a problemFND-1247814708
03HumanNon-randomized trialEfficacy outcome
In men with prostate cancer receiving testosterone-guided goserelin dosing, median castrate testosterone duration was 5.5 months, with a range of 3.5 to 10.
In plain wordsIn men with prostate cancer receiving testosterone-guided goserelin dosing, testosterone remained at castrate levels for a median 5.5 months.
Peptide
Goserelin
Outcome
Not applicableDuration of castrate testosterone
Study
n = 22
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10.8 mgAs given in this study (human).
Measurements
Median castrate testosterone duration
5.5 months
testosterone-guided re-dosing
Castrate testosterone duration range
3.5 to 10 months
testosterone-guided re-dosing
Source sentences
Summary
Median duration of castrate testosterone was 5.5 months (range 3.5 to 10).
2 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Report a problemFND-1247814701
04HumanNon-randomized trialEfficacy outcome
In men with prostate cancer receiving testosterone-guided goserelin dosing, prostate specific antigen did not change significantly from nadir during castrate duration.
In plain wordsIn men receiving testosterone-guided goserelin dosing, prostate specific antigen did not change significantly from its lowest level during castrate duration.
Peptide
Goserelin
Outcome
No significant changeProstate specific antigen
Study
n = 22
Comparator
Nadir prostate specific antigen
Outcome group
Tumor growth · Cancer
Studied dose
10.8 mgAs given in this study (human).
Source sentences
Summary
No significant change from nadir prostate specific antigen was observed during castrate duration.
2 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Report a problemFND-1247814704
05HumanNon-randomized trialOther
In men with prostate cancer, testosterone-guided goserelin re-dosing reduced yearly care costs to $3,567.90 versus $7,135.80.
In plain wordsIn men with prostate cancer, testosterone-guided goserelin re-dosing reduced yearly care costs compared with the alternative dosing method.
Peptide
Goserelin
Outcome
DecreaseYearly cost of care
Study
n = 22
Comparator
Alternative dosing method
Outcome group
Cost Of Care · Cancer
Studied dose
10.8 mgAs given in this study (human).
Measurements
Yearly care cost
3567.9 USD
testosterone-guided re-dosing
Yearly care cost
7135.8 USD
comparator
Source sentences
Summary
The yearly cost of care was significantly decreased using the method of re-dosing based on serum testosterone ($3,567.90 versus $7,135.80).
2 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Report a problemFND-1247814705
06HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, short-term patient satisfaction improved significantly from baseline with testosterone-guided goserelin re-dosing.
In plain wordsIn men with prostate cancer, short-term satisfaction improved from baseline with testosterone-guided goserelin re-dosing.
Peptide
Goserelin
Outcome
IncreaseShort-term patient satisfaction
Study
n = 22
Comparator
Baseline
Outcome group
Patient-reported outcomes · Cancer
Studied dose
10.8 mgAs given in this study (human).
Source sentences
Summary
Short-term overall health related quality of life and patient satisfaction were significantly improved over baseline measurements.
2 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Report a problemFND-1247814707
07HumanObservational studyOther
In men receiving testosterone-guided goserelin dosing, longer castrate testosterone duration correlated significantly with lower pretreatment testosterone.
In plain wordsIn men receiving testosterone-guided goserelin dosing, lower pretreatment testosterone was linked to longer castrate testosterone duration.
Peptide
Goserelin
Outcome
Not applicableCastrate duration and pretreatment testosterone
Study
n = 22
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10.8 mgAs given in this study (human).
Source sentences
Summary
Longer durations of castrate testosterone significantly correlated with lower pretreatment serum testosterone and smaller body mass index.
2 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Report a problemFND-1247814702
08HumanObservational studyOther
In men receiving testosterone-guided goserelin dosing, longer castrate testosterone duration correlated significantly with smaller body mass index.
In plain wordsIn men receiving testosterone-guided goserelin dosing, smaller body mass index was linked to longer castrate testosterone duration.
Peptide
Goserelin
Outcome
Not applicableCastrate duration and body mass index
Study
n = 22
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
10.8 mgAs given in this study (human).
Source sentences
Summary
Longer durations of castrate testosterone significantly correlated with lower pretreatment serum testosterone and smaller body mass index.
2 context sentences(design, population, supporting numbers)
Summary · context
Patient assessed health related quality of life improved in the short term and the cost of care decreased with no loss in the quality of care or patient satisfaction using serum testosterone as the trigger to re-dose 10.8 mg. goserelin in patients with prostate cancer on androgen suppression therapy.
Summary · context
The study comprised 22 patients with prostate cancer prospectively enrolled in a control-crossover designed trial of dosing depot luteinizing hormone-releasing hormone agonist based on serum testosterone.
Report a problemFND-1247814703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms